gms | German Medical Science

104th DOG Annual Meeting

21. - 24.09.2006, Berlin

Article

Send article

Diabetes – Retinal Degeneration - Octreotide

Diabetes – retinale Degeneration – Octreotid

Meeting Abstract

Search Medline for

  • G. E. Lang - Augenklinik, Universitätsklinikum Ulm

Deutsche Ophthalmologische Gesellschaft e.V.. 104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft (DOG). Berlin, 21.-24.09.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06dogDO.08.05

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dog2006/06dog064.shtml

Published: September 18, 2006

© 2006 Lang.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

The somatostatin analogue SandostatinR LARR is a possible treatment modality for patients suffering from diseases caused by a chronic overproduction of growth hormon (GH) and insulin like growth factor 1 (IGF-1). Those factors play an important role in the pathogenesis of diabetic retinopathy. The somatostatin receptors, that are expressed in the retina, are target molecules for the treatment of retinal vascular diseases like diabetic retinopathy with somatostatin analogues. Sandostatin is a promising molecule to treat advanced cases of diabetic retinopathy because it inhibits the local and systemic production of GH and IGF-1. It is well tolerated. The results of pilot studies indicate, that Sandostatin possibly can inhibit the progression of diabetic retinoathy and preserve visual acuity. The results of the two phase III trials will be presented.